What happened

Commercial waste removal specialist Stericycle (NASDAQ:SRCL) saw its stock surge 12% in early Thursday trading, before settling down to a more modest 8% move by 12 p.m. EST.

So what

As you've probably guessed, earnings had something to do with the move. Stericycle reported its fiscal Q4 and full-year earnings last night, and the numbers exceeded analyst expectations. For the fourth quarter, the company reported 2% revenue growth to $906 million (analysts had expected less than $904 million). The company earned only $0.14 per share on that revenue, but said its "non-GAAP earnings" were a full $1 per share, which exceeded analyst projections for a $0.93 profit.

For the year, Stericycle reported GAAP earnings of $2.08 per share (down 30% year over year) on sales of $3.56 billion (up 19%).

Toxic waste disposal trucks

Companies hire Stericycle to make their hazmat waste go away. Image source: Getty Images.

Now what

Management offered up no projections for how it expects to perform in 2017 to guide investors' decision on what to do next, so let me give my take instead. Based on reported earnings, Stericycle stock now costs more than 40 times earnings. That's about 33% more expensive than the stock looked heading into earnings yesterday.

On the other hand, free cash flow last year was simply brilliant, with Stericycle reporting cash profits generated of $411.2 million -- nearly twice recorded profits and a 49% improvement over last year's cash haul.

On the third hand, though, Stericycle stock now carries an enterprise value of $10.1 billion, resulting in an enterprise-value-to-free-cash-flow ratio of just 24.5 on the stock. So arguably, viewed from the perspective of EV/FCF, Stericycle stock is not just cheaper than it looks when valued on P/E, but also cheaper than it looked just 24 hours ago. Whether it's cheap enough to buy given analyst predictions that long-term growth will average only 10%, though, is another question. Personally, despite last night's great results, I vote "no."

Rich Smith has no position in any stocks mentioned. The Motley Fool recommends Stericycle. The Motley Fool has a disclosure policy.